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Fig. 1. Specificity was examined by mixing together the high, medium and low
quality control samples (mQC). This mixture was serially diluted at the following
dilutions: 1:2, 1:4, 1:8, and 1:10. The results of this serial dilution were then
compared to the standard curve that was derived using the standards provided
by the manufacturer by comparing the absorbance to the concentration. The
samples demonstrated parallelism to the master standard curve.
Fig. 2. Linearity of dilution was analyzed by serially diluting QC samples (high,
medium, and low) at the following dilutions: 1:2, 1:4, 1:8, and 1:10. The concen-
tration of each dilution was then determined from the standard curve and the
observed concentration was plotted against the reciprocal of the dilution (1/dilu-
tion).
2). There was no loss in the stability of the CTX II epitope
out to 4 freeze/thaw cycles. Differences in biological activity
were identified when examining SF samples from normal rested
horses (291 ± 58.5 pg/ml), horses treadmill exercised for 4
months (330.8 ± 124 pg/ml), and those with naturally-occurring
OC injuries (690.0 ± 69.3 pg/ml).
Conclusions: The Serum Pre-Clinical Cartilaps® ELISA is a
reproducible and valid assay for use with equine synovial fluid.
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Purpose: To date, autologous chondrocyte transplantation (ACT)
is mainly used for the treatment of post-traumatic cartilage de-
generation or of osteochondrosis dissecans (OD). First studies
suggest that ACT might also be used for the treatment of os-
teoarthritis (OA). However, it is still unclear if the environment
in the osteoarthritic joint might hamper cartilage regeneration.
Therefore, we compared matrix metalloproteases (MMP) and cy-
tokine levels in synovial fluid from patients currently treated with
ACT with those of patients with generalized, primary OA or with
unilateral OA combined with axis-malalignment.
Methods: Knee synovial fluid (SF) was collected from OD-
patients (n=6, 33 ± 10 years), post-traumatic cartilage
degeneration-patients (n=9, 39 ± 12 years), unilateral OA-
patients (n=12, 53 ± 17 years), and primary OA-patients (n=19,
71 ± 9 years). Samples were collected before the cartilage
harvest for ACT, during diagnostical arthroscopy or before total
knee replacement, immediately frozen, and stored at -70°C until
measurement.
The concentration of cytokines and MMPs were determined
using a multiplex assay based on antibody-coated microspheres
(xMAP® Technology, Luminex, USA). IL-1β, IL-6, IL-8, IL-10,
IL-12 and TNFα were measured with the Beadlyte® Human
Multi-cytokine Detection System 2 (Upstate USA, Lake Placid,
NY); MMP-1, -2, -3, -7, -8, -9, -10, and -13 were measured
using a multiplexed bead-based assay system developed at our
institute.
Results: In SF of all four groups, high concentrations of MMP-
1, -3 and -9 (av. 119.7, 471.9, 1311.8 ng/ml respectively), and
medium levels of MMP-7 (av. 20.6 ng/ml) were present; MMP-10
(av. 0.4 ng/ml) was only present at very low levels, while MMP-
2, -8, and -13 could not be detected. No differences could be
detected between the different groups, except that MMP-levels
in SF from OD-patient appeared to be generally lower than
OA and traumatic cartilage degeneration. However, this only
reached significance for MMP-3 compared with post-traumatic
cartilage degeneration. IL-6 was the cytokine found in highest
concentration in the SF of most of the patients (av. 284.8 pg/ml).
In all groups IL-8 was present in medium levels (av. 39.6 pg/ml),
while IL-1β, IL-10, IL-12 and TNFα were present at baseline (av.
3.6-16.8 pg/ml). Again, no differences between the four groups
were found.
Conclusions: We conclude that although both inflammatory
cytokines and MMPs were present in the SF of all patients,
the levels of those did not differ between the OA, the post-
trauma and OD groups. Since patients of the last two groups are
routinely treated with the ACT with good results, the presence
of these cytokines and MMPs does not hamper the success of
this method. It might therefore be expected that the metabolic
environment in OA patients also would not prevent the usage of
ACT in these patients.
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Purpose: Urine levels of C telopeptides of type I (CTX I) and II
(CTX II) collagens have been shown to be useful for the moni-
toring of patients with bone and articular diseases respectively.
The aim of the study was to assess differences of CTX I and
CTX II urine concentrations according to the musculoskeletal
diseases, and to investigate whether the levels of the biomarkers
can help for diagnosis.
